MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a s...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., (“Adimune”) and its progress in advancing ADI-100, an investigational product candidate to be studied in patients with Psoriasis, Type I Diabetes (T1D) and Stiff Person Syndrome. Adimune's mission is to address the root causes of autoimmune diseases. By harn.

ADTX

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Aditxt reports advancements in ADI-100 for autoimmune diseases.
Positive developments may enhance ADTX's market perception and valuation.

aditxt-subsidiary-adimune-to-ship-drug-substances-for-final-drug-product-formulation-of-adi-100-ahead-of-planned-clinical-trials-in-type-1-diabetes-and-psoriasis-in-germany-and-stiff-person-syndrome-at-the-mayo-clinic-in-the-u-s

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News